Catabasis Pharmaceuticals (United States)

Recent publications and citations

Top Concepts

Top subject area publications in last 5 years

Collaboration Analysis

Publications from 2021 to 2026

Latest Publications

Filter IconFilter

Showing 6 of 6 papers

  • Open Access
  • Conference Article

ON SOME PHONETIC FEATURES OF GALLAAROLIAN DIAGRAM

  • May 25, 2025
  • Dinora Abirqulova
  • Open Access
  • Conference Article

SOME PHONETIC FEATURES OF GALLAAROLIAN DIAGNOSES (On the example of the dialects of the village of Koytash)

  • May 25, 2025
  • D.abdurahmonova I.xidirova
  • Research Article
  • Citations27

Metabolism of bioconjugate therapeutics: why, when, and how?

  • Jan 02, 2020
  • Drug Metabolism Reviews
  • Hanlan Liu +5
  • Research Article
  • Citations7

Peptide therapeutics for the treatment of gastrointestinal disorders

  • Nov 04, 2017
  • Bioorganic & Medicinal Chemistry
  • Angelika Fretzen
  • Abstract
  • Citations1

P.396 - Edasalonexent (CAT-1004), an NF-kB inhibitor, enhances myotube formation in vitro, and increases exon-skipped sarcolemmal dystrophin in muscle of mdx mice

  • Sep 12, 2017
  • Neuromuscular Disorders
  • A Nichols +10
  • Open Access
  • Abstract
  • Citations6

PHASE 1 SINGLE AND MULTIPLE ASCENDING DOSE STUDY OF CAT-2003, A NOVEL ACTIVATOR OF LIPOPROTEIN LIPASE, DEMONSTRATES REDUCTIONS IN POSTPRANDIAL TRIGLYCERIDES

  • Mar 27, 2014
  • Journal of the American College of Cardiology
  • Joanne Donovan +6
Cactus Communications logo

Copyright 2026 Cactus Communications. All rights reserved.